Logo

Hikma' Kloxxado (naloxone hydrochloride) Receives the US FDA's Approval for the Treatment of Opioid Overdose

Share this

Hikma' Kloxxado (naloxone hydrochloride) Receives the US FDA's Approval for the Treatment of Opioid Overdose

Shots:

  • The US FDA approved Kloxxado (Nasal Spray- 8mg) for the emergency treatment of opioid overdose observed in respiratory and/or CNS depression in adult and pediatric patients.
  • In a survey- Narcan (Nasal Spray- 4mg) showed 34% attempted reversals used two or more doses. A separate study published in 2019 showed that the percent of overdose-related emergencies in the US requiring multiple doses of naloxone during 2013-2016 increased to 21% which represented a 43% increase over 4 years
  • Kloxxado contains double the amount of naloxone per spray as Narcan in a ready-to-use nasal spray and it is expected to be available in H2’ 21

  Ref: PRNewswire | Image: Hikma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions